Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

OBJECTIVE: To evaluate the cardiovascular safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus, in direct comparisons with DPP-4 inhibitors (DPP-4i), GLP-1 receptor agonists (GLP-1RA), or sulfonylureas, as used in routine practice. DESIGN:...

Descripción completa

Detalles Bibliográficos
Autores principales: Patorno, Elisabetta, Goldfine, Allison B, Schneeweiss, Sebastian, Everett, Brendan M, Glynn, Robert J, Liu, Jun, Kim, Seoyoung C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799855/
https://www.ncbi.nlm.nih.gov/pubmed/29437648
http://dx.doi.org/10.1136/bmj.k119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799855/
https://www.ncbi.nlm.nih.gov/pubmed/29437648
http://dx.doi.org/10.1136/bmj.k119

Ejemplares similares